Cold allodynia and hyperalgesia in neuropathic pain: the effect of N -methyl-d-aspartate (NMDA) receptor antagonist ketamine – a double-blind, cross-over comparison with alfentanil and placebo
- 1 February 2003
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Pain
- Vol. 101 (3), 229-235
- https://doi.org/10.1016/s0304-3959(02)00122-7
Abstract
Cold allodynia and hyperalgesia are frequent clinical findings in patients with neuropathic pain. While there have been several clinical studies showing the involvement of central sensitization mechanisms and N-methyl-D-aspartate (NMDA) receptor activation in mechanical allodynia/hyperalgesia and ongoing pain, the mechanisms of thermal allodynia and hyperalgesia have received less attention. The aim of the present study was to examine the effect of the NMDA-receptor antagonist ketamine on thermal allodynia/hyperalgesia, ongoing pain and mechanical allodynia/hyperalgesia in patients with neuropathic pain (11 patients with post-traumatic neuralgia and one patient with post-herpetic neuralgia). All the patients were known to suffer from severe cold allodynia (cold pain detection threshold (CPDT): 23.8 degrees C, median value). The mu-opioid agonist alfentanil was used as an active control. The study design was double-blind and placebo-controlled and the drugs were administered i.v. (bolus dose and infusion). CPDT in the asymptomatic contralateral area was found to be significantly decreased (cold allodynia) compared to CPDT in site- and age-matched normal controls. Heat pain detection thresholds were found to be normal and no consistent heat hyperalgesia occurred. Alfentanil significantly reduced cold allodynia (by increasing CPDT) in symptomatic area (P=0.0076). Ketamine did not significantly increase the threshold. Significant and marked reductions of hyperalgesia to cold (visual analogue score at threshold value) were seen following both alfentanil (4.5 before, 1.4 after, median value) and ketamine (6.8 before, 0.4 after, median value). Alfentanil and ketamine also significantly reduced ongoing pain and mechanical hyperalgesia. It is concluded that NMDA-receptor mediated central sensitization is involved in cold hyperalgesia, but since CPDT remained unaltered, it is likely that other mechanisms are present.Keywords
This publication has 19 references indexed in Scilit:
- Intravenous lidocaine in central painNeurology, 2000
- Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humansBritish Journal of Anaesthesia, 1996
- NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloridePain, 1996
- Central Dysesthesia Pain after Traumatic Spinal Cord Injury Is Dependent on N-Methyl-D-aspartate Receptor ActivationNeurosurgery, 1995
- Relief of post-herpetic neuralgia with the Symbol receptor antagonist ketamine: A double-blind, cross-over comparison with morphine and placeboPain, 1994
- The triple cold syndromeBrain, 1994
- Activity-dependent neuronal plasticity following tissue injury and inflammationTrends in Neurosciences, 1992
- The NMDA-receptor antagonist CPP abolishes neurogenic ‘wind-up pain’ after intrathecal administration in humansPain, 1992
- Evidence for spinalN-methyl-d-aspartate receptor involvement in prolonged chemical nociception in the ratBrain Research, 1990
- Lack of analgesic effect of opioids on neuropathic and idiopathic forms of painPain, 1988